$5.4 B

AGIO Mkt cap, 14-Jun-2018

$8.8 M

Agios Pharmaceuticals Revenue Q1, 2018
Agios Pharmaceuticals Net income (Q1, 2018)-90.8 M
Agios Pharmaceuticals EBIT (Q1, 2018)-94 M
Agios Pharmaceuticals Cash, 31-Mar-2018364.5 M

Agios Pharmaceuticals Financials

Agios Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25.5 m65.4 m59.1 m69.9 m43 m

Revenue growth, %

156%(10%)18%

R&D expense

292.7 m

General and administrative expense

71.1 m

Operating expense total

363.8 m

EBIT

(38.9 m)(54.1 m)(118.7 m)(201 m)(320.8 m)

EBIT margin, %

(152%)(83%)(201%)(288%)(746%)

Interest income

55 k203 k968 k2.5 m6.1 m

Pre tax profit

(117.7 m)(198.5 m)

Income tax expense

579 k(426 k)(426 k)

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)(314.7 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

6.3 m8.4 m34.2 m13.2 m5.5 m31.3 m7 m9 m10.5 m11.4 m8.8 m

R&D expense

14.8 m17.4 m22.6 m25.5 m32.4 m36.4 m36 m44 m50.8 m60.6 m62.7 m79.8 m72.9 m78.2 m

General and administrative expense

2.5 m3.3 m4.2 m5.2 m7 m8.9 m9.9 m10.8 m12.6 m11.9 m14.8 m16.1 m17.5 m24.6 m

Operating expense total

17.3 m20.7 m26.7 m30.7 m39.4 m45.4 m46 m54.9 m63.4 m72.5 m77.6 m95.9 m90.4 m102.8 m

EBIT

(11.1 m)(12.3 m)(18.3 m)3.2 m(5.2 m)(32.1 m)(40.5 m)(23.6 m)(56.5 m)(63.5 m)(67 m)(84.6 m)(79 m)(94 m)

EBIT margin, %

(177%)(218%)(15%)(243%)(739%)(75%)(809%)(707%)(638%)(696%)(1073%)

Interest income

13 k36 k34 k48 k238 k236 k218 k396 k517 k678 k881 k1.5 m1.9 m3.2 m

Pre tax profit

(12.2 m)(18.3 m)3.3 m

Income tax expense

121 k(448 k)

Net Income

(11.2 m)(12.2 m)(18.3 m)3.7 m(5 m)(31.9 m)(40.3 m)(23.2 m)(56 m)(62.8 m)(66.2 m)(83.1 m)(77.1 m)(90.8 m)

Agios Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6 m14 m71.8 m160.8 m102.7 m

Accounts Receivable

2.3 m600 k

Inventories

2.5 m4.8 m8.7 m10.3 m

Current Assets

169.7 m359.5 m337.3 m559.9 m445.3 m

PP&E

3.8 m6.4 m23.2 m25.3 m24.4 m

Total Assets

201.2 m491.9 m420.1 m619.1 m614.4 m

Accounts Payable

3.7 m11.1 m14.7 m17.1 m22.8 m

Short-term debt

Current Liabilities

36.9 m61.1 m52.9 m88.4 m94.9 m

Long-term debt

Total Liabilities

238.9 m

Preferred Stock

Additional Paid-in Capital

244.9 m591.3 m630.1 m842 m1.2 b

Retained Earnings

(113.4 m)(166.9 m)(284.7 m)(483.2 m)(798.1 m)

Total Equity

131.5 m424.4 m345.1 m358.6 m375.5 m

Financial Leverage

1.5 x1.2 x1.2 x1.7 x1.6 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

106 m32.8 m108.2 m70 m35.3 m72.5 m80 m39 m234 m285.5 m200.3 m138.7 m132.7 m364.5 m

Current Assets

198.8 m172.4 m245.2 m247.6 m364.1 m390.2 m371.7 m329.5 m484.2 m600.9 m506.9 m604.7 m528.3 m803 m

PP&E

3.6 m3.5 m3.2 m3.7 m14.3 m19.3 m21.1 m23 m25.1 m26.3 m24.1 m24.8 m24 m23.7 m

Total Assets

219.1 m181.9 m272 m269.6 m474.3 m474.4 m449.1 m396.1 m557.6 m672 m557.3 m760.6 m687.2 m1 b

Accounts Payable

2.1 m4.4 m5.4 m6.2 m12.6 m8.9 m9 m13.7 m18.4 m15.4 m16.2 m23.4 m17.9 m17.9 m

Current Liabilities

37.4 m34.1 m44.6 m35.1 m36.4 m45.2 m49.8 m45.1 m67.3 m78 m82.4 m93.6 m88.1 m74.7 m

Total Liabilities

251.6 m237.4 m174.5 m

Additional Paid-in Capital

243.6 m247 m344.5 m347.9 m598.5 m607.7 m619.5 m640.1 m652.6 m828 m857.1 m1.1 b1.2 b1.7 b

Retained Earnings

(101.1 m)(125.7 m)(144 m)(140.3 m)(171.9 m)(203.8 m)(244.1 m)(307.9 m)(363.8 m)(426.7 m)(549.6 m)(632.6 m)(709.8 m)(849.4 m)

Total Equity

142.6 m121.3 m200.5 m207.7 m426.8 m404.2 m375.7 m332.4 m289.1 m401.4 m307.4 m509 m449.8 m865.6 m

Financial Leverage

1.5 x1.5 x1.4 x1.3 x1.1 x1.2 x1.2 x1.2 x1.9 x1.7 x1.8 x1.5 x1.5 x1.2 x

Agios Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)(314.7 m)

Depreciation and Amortization

1.4 m1.4 m3.3 m5.7 m6.4 m

Accounts Receivable

(2.3 m)(1 m)

Inventories

Accounts Payable

30 k7.6 m4.2 m3.5 m5.3 m

Cash From Operating Activities

(56.4 m)(59.4 m)(76.9 m)38.6 m(285.2 m)

Purchases of PP&E

(1.3 m)(2.2 m)(20.2 m)(9.9 m)(4.6 m)

Cash From Investing Activities

(87.2 m)(333.3 m)128.3 m(119.4 m)(57.9 m)

Cash From Financing Activities

123.9 m335.2 m6.4 m169.8 m285.1 m

Income Taxes Paid

6 m6 m6 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(11.2 m)(12.2 m)(18.3 m)3.7 m(5 m)(36.9 m)(77.1 m)(23.2 m)(79.2 m)(142 m)(66.2 m)(149.2 m)(226.4 m)(90.8 m)

Depreciation and Amortization

1.2 m2.2 m1.2 m2.6 m4 m1.6 m3.2 m4.8 m1.7 m

Accounts Receivable

(2.9 m)(659 k)

Accounts Payable

5.4 m6.2 m12.6 m(1.2 m)(1.3 m)(293 k)3.8 m1.7 m(994 k)4.9 m742 k(4.5 m)

Cash From Operating Activities

(21.6 m)(46.4 m)(19 m)138.8 m89.8 m(74.1 m)(133.1 m)(210.8 m)(99 m)

Purchases of PP&E

(14.7 m)(18 m)(2.5 m)(5.3 m)(8.7 m)(293 k)(1.3 m)(3.3 m)(1.4 m)

Cash From Investing Activities

77.2 m107.4 m(14.8 m)20.9 m(41.8 m)109.6 m(166.2 m)(99.8 m)(167.5 m)

Cash From Financing Activities

2.9 m5.1 m1.1 m2.6 m165.8 m4 m277.2 m282.5 m528.3 m

Income Taxes Paid

6 m6 m

Agios Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information